Wesfarmers Centre of Vaccines & Infectious Diseases
What is an adaptive trial?
Team
Infectious Disease Implementation Research projects
Resources
Extra whooping cough shot to protect your bub
Professor Tom Snelling
Reports and Findings
A single blinded, phase IV, adaptive randomised control trial to evaluate the safety of coadministration of seasonal influenza and COVID-19 vaccines (The FluVID study)
We evaluated the frequency of moderate and severe adverse events following coadministration of seasonal influenza vaccine (SIV) versus placebo with COVID-19 vaccines among adults to support practice guidelines.
Published research Immunisation Influenza Infectious Diseases Infectious Disease Implementation Research Subsite: Wesfarmers Centre of Vaccines and Infectious Diseases COVID-19FeBRILe3: Safety Evaluation of Febrile Infant Guidelines Through Prospective Bayesian Monitoring
Despite evidence supporting earlier discharge of well-appearing febrile infants at low risk of serious bacterial infection (SBI), admissions for ≥48 hours remain common. Prospective safety monitoring may support broader guideline implementation.
Infectious Disease Implementation Research Vaccine Trials Group Subsite: Wesfarmers Centre of Vaccines and Infectious Diseases Child and adolescent healthInfluenza vaccination in Western Australian children: Exploring the health benefits and cost savings of increased vaccine coverage in children
To assess potential benefits and direct healthcare cost savings with expansion of an existing childhood influenza immunisation program, we developed a dynamic transmission model for the state of Western Australia, evaluating increasing coverage in children < 5 years and routinely immunising school-aged children.
Published research Immunisation Influenza Child Disability Infectious Disease Implementation Research Infectious Diseases Epidemiology Vaccine Trials Group Subsite: Wesfarmers Centre of Vaccines and Infectious Diseases Child and adolescent healthIndividual variation in vaccine immune response can produce bimodal distributions of protection
The ability for vaccines to protect against infectious diseases varies among individuals, but computational models employed to inform policy typically do not account for this variation. Here we examine this issue: we implement a model of vaccine efficacy developed in the context of SARS-CoV-2 in order to evaluate the general implications of modelling correlates of protection on the individual level.
Published research Immunisation Infectious Disease Implementation Research Geospatial Health and Development COVID-19